NCT06598943

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Detailed description

The study will last approximately 4-5 years. Screening is required within 35 days prior to enrollment. For each participant, the total duration of the clinical trial will be about 69 weeks including screening.

Conditions

• Ulcerative Colitis
• Ulcerative Colitis Chronic

Interventions

Type	Name	Description
DRUG	Eltrekibart	Administered
DRUG	Mirikizumab	Administered
DRUG	Placebo	Administered

Timeline

• Start date: 2024-10-10
• Primary completion: 2027-12-01
• Completion: 2028-09-01
• First posted: 2024-09-19
• Last updated: 2026-03-03

Locations

207 sites across 21 countries: United States, Argentina, Belgium, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Latvia, Poland, Romania, Serbia, Spain, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study